Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Clinical Trials of Potentially 'Game-Changing' Immunotherapy Drug for Advanced Prostate ...

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at news.cuanschutz.edu →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Two clinical trials at the University of Colorado Anschutz Cancer Center are testing pasritamig, a novel bispecific T-cell engager immunotherapy drug for advanced, hormone-resistant prostate cancer, showing promising safety and efficacy signals in early studies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Advance in immunotherapy for prostate cancer moves from promise to early validation, making this a critical moment for biotech founders focused on oncology to explore combination therapies and patient targeting approaches.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechimmunotherapyprostate-cancerclinical-trialsbiotechpasritamig